US OptionsDetailed Quotes
INCY241220C90000
- 1.40
- +0.45+47.37%
15min DelayClose Nov 27 16:00 ET
1.40High1.40Low
1.40Open0.95Pre Close2 Volume2.72K Open Interest90.00Strike Price280.00Turnover91.70%IV21.14%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry1.40Extrinsic Value100Contract SizeAmericanOptions Type0.2585Delta0.0188Gamma31.44Leverage Ratio-0.1259Theta0.0106Rho8.13Eff Leverage0.0606Vega
Incyte Stock Discussion
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)
$Humacyte (HUMA.US)$ : 🤔
⇨ Human Acellular Vessel (HAV)™
‣ Vascular Trauma
‣ PDUFA: 8/10/24 (BLA)
🗓️ Last Week’s AdCom & PDUFAs:
$Zevra Therapeutics (ZVRA.US)$ : Favorable AdCom 👍
🗳️ 11-5 votes in favor
⇨ Arimoclomol
‣ Niemann-Pick disease type C
‣ AdCom: 8/2/24 (NDA)
$Adaptimmune Therapeutics (ADAP.US)$ : Approved 🎉
⇨ TECELRA (afamitresgene autoleucel)
‣ Synovial sarcoma
‣ PDUFA: 8/4/24 (BLA)
$GlaxoSmithKline (GSK.US)$ : Approved 🎉
⇨ Jemperli
‣ Endometria...
Gapping up
$Paramount Global-B (PARA.US)$ 's stock increased by 3.85% following a report from the New York Times that billionaire Barry Diller is considering a takeover bid for the company after the studio he used to lead withdrew from a merger with Skydance Media.
$PayPal (PYPL.US)$ shares rose by 1.39% after Susquehanna raised its rating from Neutral to Positive.
Gapping down
$Tesla (TSLA.US)$ 's stock declined ...
I managed to garner an average of 3% a month the past 4 months using several methods of trading.
I started trading about 6 months ago with a small sum to test the waters until I was fully ready to begin my journey in March.
Trading is relatively simple if you just try to minimize your risk as much as possible and just throw that gambler's mindset into the bin...
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led ...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...
No comment yet